Colorectal cancer phd thesis

About the Lerner Research Institute  The Lerner Research Institute is home to Cleveland Clinic’s laboratory, translational and clinical research. Its mission is to promote human health by investigating in the laboratory and the clinic the causes of disease and discovering novel approaches to prevention and treatments; to train the next generation of biomedical researchers; and to foster productive collaborations with those providing clinical care. Lerner researchers publish ~1,500 articles in peer-reviewed biomedical journals each year.  Lerner’s total annual research expenditure was $260 million in 2016 (with $140 million in competitive federal funding, placing Lerner in the top five research institutes in the nation in federal grant funding). Approximately 1,500 people (including approximately 200 principal investigators, 240 research fellows, and about 150 graduate students) in 12 departments work in research programs focusing on heart and vascular, cancer, brain, eye, metabolic, musculoskeletal, inflammatory and fibrotic diseases. The Lerner has more than 700,000 square feet of lab, office and scientific core services space. Lerner faculty oversee the curriculum and teach students enrolled in the Cleveland Clinic Lerner College of Medicine (CCLCM) of Case Western Reserve University – training the next generation of physician-scientists. Institute faculty also participate in multiple doctoral programs, including the Molecular Medicine PhD Program, which integrates traditional graduate training with an emphasis on human diseases. The Lerner is a significant source of commercial property, generating 64 invention disclosures, 15 licenses, 121 patents, and one new spinoff company in 2016. Visit us at . Follow us on Twitter at /CCLRI.

Grivennikov et al. (2012) investigated mechanisms responsible for tumor-elicited inflammation in a mouse model of colorectal tumorigenesis which, like human colorectal cancer, exhibits upregulation of IL23 ( 605580 ) and IL17 ( 603149 ). They showed that IL23 signaling promotes tumor growth and progression, and development of tumoral IL17 response. IL23 is mainly produced by tumor-associated myeloid cells that are likely to be activated by microbial products, which penetrate the tumors but not adjacent tissue. Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins. Grivennikov et al. (2012) proposed that barrier deterioration induced by colorectal cancer-initiating genetic lesions results in adenoma invasion by microbial products that trigger tumor-elicited inflammation, which in turn drives tumor growth.

Colorectal cancer phd thesis

colorectal cancer phd thesis


colorectal cancer phd thesiscolorectal cancer phd thesiscolorectal cancer phd thesiscolorectal cancer phd thesis